RecruitingPhase 1NCT07224087

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Development of a Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

Sponsor

Yale University

Enrollment

20 participants

Start Date

Mar 2, 2026

Study Type

INTERVENTIONAL

Conditions

Obesity Smoking Cessation Bariatric Surgery Patients

Summary

The purpose of this research study is to develop and pilot a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bupropion HCl Extended Release, Cognitive-Behavioral Therapy, and others for people with bariatric surgery patients, obesity, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNaltrexone Hydrochloride

Participants will be given 50mg/day of Naltrexone for 4 months.

DRUGBupropion HCl Extended Release

Participants will be given 300mg/day of Bupropion for 4 months. Bupropion will be taken twice daily (150mg in the morning, followed by 150mg in the late afternoon/early evening).

BEHAVIORALCognitive-Behavioral Therapy

Participants will receive cognitive-behavioral therapy for weight loss and smoking cessation. Participants will meet with their assigned study clinician weekly for 60 minutes for 4 months.